, N Engl J Med, vol.365, pp.1118-1127, 2011.
, Lancet, vol.379, pp.1245-1255, 2012.
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.29, pp.238-255, 2018. ,
, European Association for the Study of the LiverEuropean Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma, J Hepatol, vol.69, pp.182-236, 2018.
Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification, J Hepatol, 2017. ,
Clinicopathological indices to predict hepatocellular carcinoma molecular classification, Liver Int, 2015. ,
Cholestasis is a marker for hepatocellular carcinomas displaying beta-catenin mutations, J Pathol, vol.212, pp.345-352, 2007. ,
MacSween's pathology of the liver ,
, Bosman FTWorld Health OrganizationInternational Agency for Research on Cancer. WHO classification of tumours of the digestive system, 2010.
Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis, Hepatology, vol.45, pp.725-734, 2007. ,
, Histopathology of hepatocellular carcinoma. Recent Results Cancer Res, vol.190, pp.21-32, 2013.
Genetic landscape and biomarkers of hepatocellular carcinoma, Gastroenterology, vol.149, pp.1226-1239, 2015. ,
A genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification, Hepatology, 2014. ,
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets, Nat Genet, vol.47, pp.505-511, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-01159736
Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma, Nat Genet, vol.44, pp.694-698, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-00719917
Trans-ancestry mutational landscape of hepatocellular carcinoma genomes, Nat Genet, vol.46, pp.1267-1273, 2014. ,
High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions, Nat Commun, vol.4, p.2218, 2013. ,
Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma, Cancer Res, vol.69, pp.7385-7392, 2009. ,
Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets, Hepatology, vol.45, pp.42-52, 2007. ,
URL : https://hal.archives-ouvertes.fr/inserm-00130313
, Cancer Genome Atlas Research Network, Cancer Genome Atlas Research N. Comprehensive and integrative genomic characterization of hepatocellular carcinoma, Cell, vol.169, pp.1327-1341, 1323.
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma, Cancer Res, vol.68, pp.6779-6788, 2008. ,
Molecular therapies and precision medicine for hepatocellular carcinoma, Nat Rev Clin Oncol, vol.15, pp.599-616, 2018. ,
Advances in targeted therapies for hepatocellular carcinoma in the genomic era, Nat Rev Clin Oncol, vol.12, p.436, 2015. ,
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling, Hepatology, vol.40, pp.667-676, 2004. ,
Beta-catenin signaling and roles in liver homeostasis, injury, and tumorigenesis, Gastroenterology, vol.148, pp.1294-1310, 2015. ,
T-cell factor 4 and beta-catenin chromatin occupancies pattern zonal liver metabolism in mice, Hepatology, vol.59, pp.2344-2357, 2014. ,
OATP1B3 expression is strongly associated with Wnt/beta-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma, J Hepatol, vol.61, pp.1080-1087, 2014. ,
Macrotrabecular-massive hepatocellular carcinoma: a distinctive histological subtype with clinical relevance, Hepatology, vol.68, pp.103-112, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01744935
Tumorderived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer, Cancer Res, vol.63, pp.3403-3412, 2003. ,
Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy, Cancer Res, vol.73, pp.1649-1657, 2013. ,
A fibrous stromal component in hepatocellular carcinoma reveals a cholangiocarcinoma-like gene expression trait and epithelial-mesenchymal transition, Hepatology, vol.55, pp.1776-1786, 2012. ,
Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH, Am J Surg Pathol, vol.34, pp.1630-1636, 2010. ,
The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis, Hum Pathol, vol.43, pp.737-746, 2012. ,
Tumor stroma with senescence-associated secretory phenotype in steatohepatitic hepatocellular carcinoma, PLoS One, vol.12, p.171922, 2017. ,
beta-catenin alteration is rare in hepatocellular carcinoma with steatohepatitic features: immunohistochemical and mutational study, Virchows Archiv, 2015. ,
Characterization of inflammatory (lymphoepithelioma-like) hepatocellular carcinoma: a study of 8 cases, Arch Pathol Lab Med, vol.138, pp.1193-1202, 2014. ,
Lessons from rare tumors: hepatic lymphoepithelioma-like carcinomas, World J Gastroenterol, vol.21, pp.3472-3479, 2015. ,
Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome, Am J Surg Pathol, vol.39, pp.304-312, 2015. ,
Lymphoepithelioma-like carcinoma in liver, Am J Pathol, vol.187, pp.1438-1444, 2017. ,
Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features, Hepatology, vol.64, pp.2038-2046, 2016. ,
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival, Genome Res, vol.24, pp.743-750, 2014. ,
Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer, Lung Cancer, vol.118, pp.57-61, 2018. ,
Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma, Oncotarget, vol.9, pp.7949-7960, 2018. ,
Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis, Lancet Oncol, vol.18, pp.1009-1021, 2017. ,
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade, Science, vol.351, pp.1463-1469, 2016. ,
Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features, Gastroenterology, vol.153, pp.812-826, 2017. ,
The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin, Histopathology, vol.49, pp.138-151, 2006. ,
A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells, Nat Med, vol.12, pp.410-416, 2006. ,
Modeling pathogenesis of primary liver cancer in lineagespecific mouse cell types, Gastroenterology, vol.145, pp.221-231, 2013. ,
Hypoxia after transarterial chemoembolization may trigger a progenitor cell phenotype in hepatocellular carcinoma, Histopathology, vol.67, pp.442-450, 2015. ,
Impact of stem cell marker expression on recurrence of TACE-treated hepatocellular carcinoma post liver transplantation, BMC Cancer, vol.12, p.584, 2012. ,
Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation, Liver Transplant, vol.17, pp.943-954, 2011. ,
Sublethal heat treatment promotes epithelialmesenchymal transition and enhances the malignant potential of hepatocellular carcinoma, Hepatology, vol.59, p.1650, 2014. ,
CRISPR/Cas9 engineering of adult mouse liver demonstrates that the dnajb1-prkaca gene fusion is sufficient to induce tumors resembling fibrolamellar hepatocellular carcinoma, Gastroenterology, vol.153, pp.1662-1673, 1610. ,
DNAJB1-PRKACA fusion kinase interacts with betacatenin and the liver regenerative response to drive fibrolamellar hepatocellular carcinoma, PNAS, vol.114, pp.13076-13084, 2017. ,
Methylome sequencing for fibrolamellar hepatocellular carcinoma depicts distinctive features, Epigenetics, vol.10, pp.872-881, 2015. ,
A genomic case study of mixed fibrolamellar hepatocellular carcinoma, Ann Oncol, vol.27, pp.1148-1154, 2016. ,
Pure and mixed fibrolamellar hepatocellular carcinomas differ in natural history and prognosis after complete surgical resection, Cancer, vol.118, pp.4981-4990, 2012. ,
Transcriptional profiling of pure fibrolamellar hepatocellular carcinoma reveals an endocrine signature, Hepatology, vol.59, pp.2228-2237, 2014. ,
Model of fibrolamellar hepatocellular carcinomas reveals striking enrichment in cancer stem cells, Nat Commun, vol.6, p.8070, 2015. ,
Mixed hepatocellular cholangiocarcinoma tumors: cholangiolocellular carcinoma is a distinct molecular entity, J Hepatol, vol.66, pp.952-961, 2017. ,
Whole-exome sequencing reveals the origin and evolution of hepato-cholangiocarcinoma, Nat Commun, vol.9, p.894, 2018. ,
Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy, Cancer Chemother Pharmacol, vol.23, pp.4-8, 1989. ,
Combined hepatocellular carcinoma and neuroendocrine carcinoma with sarcomatous change of the liver after transarterial chemoembolization, Hepatol Res, vol.42, pp.1141-1145, 2012. ,
Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features, Mod Pathol, vol.26, pp.1586-1593, 2013. ,
Alternative lengthening of telomeres: models, mechanisms and implications, Nat Rev Genet, vol.11, pp.319-330, 2010. ,
Altered telomeres in tumors with ATRX and DAXX mutations, Science, vol.333, p.425, 2011. ,
Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma, Nature, vol.482, pp.226-231, 2012. ,
Granulocyte colony-stimulating factor-producing hepatocellular carcinoma with abrupt changes, World J Clin Oncol, vol.7, pp.380-386, 2016. ,
Carcinosarcoma of the liver producing granulocytecolony stimulating factor, Pathol Int, vol.56, pp.413-419, 2006. ,
A case of granulocyte-colony stimulating factor-producing hepatocellular carcinoma confirmed by immunohistochemistry, J Korean Med Sci, vol.25, pp.476-480, 2010. ,
Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape, Clin Cancer Res, vol.23, pp.6686-6696, 2017. ,
Variant histology in bladder cancer: how it should change the management in non-muscle invasive and muscle invasive disease?, Transl Androl Urol, vol.5, pp.692-701, 2016. ,
Micropapillary bladder cancer: current treatment patterns and review of the literature, Urol Oncol, vol.32, pp.826-832, 2014. ,
Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation, Oncology, vol.80, pp.278-288, 2011. ,
Human hepatocellular carcinomas with ''Stemness"-related marker expression: keratin 19 expression and a poor prognosis, Hepatology, vol.54, pp.1707-1717, 2011. ,
Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection, Clin Cancer Res, vol.14, pp.3850-3859, 2008. ,
Clinical manifestations and outcomes of patients with sarcomatoid hepatocellular carcinoma, Hepatology, 2018. ,
The immune microenvironment of human tumors: general significance and clinical impact, Cancer Microenviron, vol.6, pp.117-122, 2013. ,
The immune contexture in cancer prognosis and treatment, Nat Rev Clin Oncol, 2017. ,
The prognostic value of tumor-infiltrating lymphocytes in hepatocellular carcinoma: a systematic review and meta-analysis, Sci Rep, vol.7, p.7525, 2017. ,
Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification, Hepatology, vol.68, pp.1025-1041, 2018. ,
Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma, J Hepatol, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-02536028
Biomarkers associated with response to regorafenib in patients with hepatocellular carcinoma, Gastroenterology, vol.156, pp.1731-1741, 2019. ,
Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial, 2018. ,
Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design, Clin Cancer Res, vol.20, pp.2072-2079, 2014. ,
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study, J Clin Oncol, vol.31, pp.3509-3516, 2013. ,
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study, Lancet Oncol, vol.19, pp.682-693, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02337178
Proliferation markers are associated with MET expression in hepatocellular carcinoma and predict tivantinib sensitivity in vitro, Clin Cancer Res, vol.23, pp.4364-4375, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-02450533
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol, vol.20, pp.282-296, 2019. ,
Systemic therapy for hepatocellular carcinoma: latest advances, Cancers (Basel), vol.10, 2018. ,
Immunotherapy of hepatocellular carcinoma: facts and hopes, Clin Cancer Res, vol.24, pp.1518-1524, 2018. ,
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial, Lancet Oncol, vol.19, pp.940-952, 2018. ,
PD-L1 expression as a predictive biomarker in cancer immunotherapy, Mol Cancer Ther, vol.14, pp.847-856, 2015. ,
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study, Lancet, vol.391, pp.2128-2139, 2018. ,
The Immune landscape of cancer, Immunity, vol.48, pp.812-830, 2018. ,
Targeting Wnt/beta-catenin signaling for cancer immunotherapy, Trends Pharmacol Sci, vol.39, pp.648-658, 2018. ,
Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity, Nature, vol.523, pp.231-235, 2015. ,
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy, Nat Rev Cancer, vol.19, pp.133-150, 2019. ,
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors, Mol Cancer, vol.17, p.129, 2018. ,
Predictive biomarkers for checkpoint inhibitor-based immunotherapy, Lancet Oncol, vol.17, pp.542-551, 2016. ,
Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma, Br J Cancer, vol.119, pp.80-88, 2018. ,
Liver cancer biopsy-back to the future?, Hepatology, vol.61, pp.431-433, 2015. ,
, First-line crizotinib versus chemotherapy in ALK-positive lung cancer, N Engl J Med, vol.373, p.1582, 2015.
Crizotinib versus chemotherapy in advanced ALK-positive lung cancer, N Engl J Med, vol.368, pp.2385-2394, 2013. ,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N Engl J Med, vol.350, pp.2129-2139, 2004. ,
PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, vol.372, pp.2509-2520, 2015. ,
Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, vol.364, pp.2507-2516, 2011. ,
Biopsy for liver cancer: how to balance research needs with evidence-based clinical practice, Hepatology, vol.61, pp.433-436, 2015. ,
Trunk mutational events present minimal intra-and intertumoral heterogeneity in hepatocellular carcinoma, J Hepatol, vol.67, pp.1222-1231, 2017. ,
Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma, Gastroenterology, vol.140, pp.1501-1512, 2011. ,
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, vol.66, pp.3992-3995, 2006. ,
Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers, Mol Cancer Ther, vol.16, pp.2598-2608, 2017. ,
Tumor Mutational Burden and Response Rate to PD-1 Inhibition, N Engl J Med, vol.377, pp.2500-2501, 2017. ,
Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer, Cancer Cell, vol.33, pp.853-861, 2018. ,
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, vol.348, pp.124-128, 2015. ,
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer, N Engl J Med, vol.351, pp.2817-2826, 2004. ,
Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer, N Engl J Med, 2018. ,
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, vol.387, pp.1909-1920, 2016. ,
Impact of 70-gene signature use on adjuvant chemotherapy decisions in patients with estrogen receptor-positive early breast cancer: results of a prospective cohort study, J Clin Oncol, vol.35, pp.2814-2819, 2017. ,
A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection, Gastroenterology, vol.145, pp.176-187, 2013. ,
Pembrolizumab versus chemotherapy for PD-L1-positive nonsmall-cell lung cancer, N Engl J Med, vol.375, pp.1823-1833, 2016. ,
Personalized therapy for breast cancer, Clin Genet, vol.86, pp.62-67, 2014. ,
PD-L1 testing in non-small cell lung carcinoma: guidelines from the PATTERN group of thoracic pathologists, Ann Pathol, vol.38, pp.110-125, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-01927078
Clinical significance of histologic variants of bladder cancer, J Natl Compr Canc Netw, vol.15, pp.1268-1274, 2017. ,
Sarcomatoid renal cell carcinoma: Biology and treatment advances, Urologic Oncol, vol.36, pp.265-271, 2018. ,
Everolimus versus sunitinib prospective evaluation in metastatic nonclear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial, Eur Urol, vol.69, pp.866-874, 2016. ,
Phase 2 trial of capecitabine, gemcitabine, and bevacizumab in sarcomatoid renal-cell carcinoma, Clin Genitourin Cancer, 2017. ,
Machine learning methods for histopathological image analysis, Comput Struct Biotechnol J, vol.16, pp.34-42, 2018. ,
Predicting non-small cell lung cancer prognosis by fully automated microscopic pathology image features, Nat Commun, vol.7, p.12474, 2016. ,
Predicting cancer outcomes from histology and genomics using convolutional networks, PNAS, vol.115, pp.2970-2979, 2018. ,
Precision histology: how deep learning is poised to revitalize histomorphology for personalized cancer care, NPJ Precis Oncol, vol.1, p.22, 2017. ,
Predicting survival from colorectal cancer histology slides using deep learning: a retrospective multicenter study, PLoS Med, vol.16, p.1002730, 2019. ,
Pathologist-level classification of histologic patterns on resected lung adenocarcinoma slides with deep neural networks, Sci Rep, vol.9, p.3358, 2019. ,
Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning, Nat Med, vol.24, pp.1559-1567, 2018. ,